Editas Medicine Inc (EDIT)
2.865
-0.04
(-1.55%)
USD |
NASDAQ |
Nov 04, 16:00
2.88
+0.02
(+0.52%)
After-Hours: 20:00
Editas Medicine Enterprise Value: -39.11M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | -39.11M |
| October 31, 2024 | -39.93M |
| October 30, 2024 | -30.03M |
| October 29, 2024 | -22.61M |
| October 28, 2024 | -10.24M |
| October 25, 2024 | -16.84M |
| October 24, 2024 | -16.84M |
| October 23, 2024 | -14.36M |
| October 22, 2024 | -7.765M |
| October 21, 2024 | 31.00M |
| October 18, 2024 | -1.991M |
| October 17, 2024 | -6.115M |
| October 16, 2024 | 5.432M |
| October 15, 2024 | -1.991M |
| October 14, 2024 | -11.89M |
| October 11, 2024 | -16.01M |
| October 10, 2024 | -34.98M |
| October 09, 2024 | -21.79M |
| October 08, 2024 | -17.66M |
| October 07, 2024 | -14.36M |
| October 04, 2024 | -0.3418M |
| October 03, 2024 | -15.19M |
| October 02, 2024 | -13.54M |
| October 01, 2024 | -9.414M |
| September 30, 2024 | 2.132M |
| Date | Value |
|---|---|
| September 27, 2024 | 7.906M |
| September 26, 2024 | 8.731M |
| September 25, 2024 | 0.483M |
| September 24, 2024 | 12.03M |
| September 23, 2024 | 22.75M |
| September 20, 2024 | 31.82M |
| September 19, 2024 | 43.37M |
| September 18, 2024 | 40.90M |
| September 17, 2024 | 39.25M |
| September 16, 2024 | 36.77M |
| September 13, 2024 | 46.67M |
| September 12, 2024 | 30.17M |
| September 11, 2024 | 32.65M |
| September 10, 2024 | 31.82M |
| September 09, 2024 | 10.38M |
| September 06, 2024 | 16.98M |
| September 05, 2024 | 8.731M |
| September 04, 2024 | 9.555M |
| September 03, 2024 | 8.731M |
| August 30, 2024 | 29.35M |
| August 29, 2024 | 26.88M |
| August 28, 2024 | 24.40M |
| August 27, 2024 | 35.95M |
| August 26, 2024 | 44.20M |
| August 23, 2024 | 40.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-39.93M
Minimum
Oct 31 2024
5.265B
Maximum
Jan 08 2021
1.009B
Average
601.38M
Median
Enterprise Value Benchmarks
| EyePoint Pharmaceuticals Inc | 365.18M |
| Cassava Sciences Inc | 1.050B |
| Regeneron Pharmaceuticals Inc | 84.89B |
| Vertex Pharmaceuticals Inc | 115.80B |
| Adverum Biotechnologies Inc | -19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.61M |
| Revenue (Quarterly) | 0.513M |
| Total Expenses (Quarterly) | 72.42M |
| EPS Diluted (Quarterly) | -0.82 |
| Profit Margin (Quarterly) | -13.18K% |
| Earnings Yield | -82.37% |
| Normalized Earnings Yield | -82.37 |